The companies aim to produce more than 100 million doses of the CureVac vaccine per year in Laupheim
The company also announced the addition of Dr Ralf Smit to its executive board
The launch of the product follows approval by the US FDA
Biosimilar development in the United States is at an important juncture, reports Darren Mansell, Regulatory Affairs ...
The agreement aims to to advance point-of-care development and commercialisation of cell and gene therapies
The agreement does not include Artios’s lead programmes, Polθ and ATR inhibitors, for which it will retain all rights
Today’s market for topical pharmaceuticals is valued at around $95 billion, with development efforts focused on small ...
On October 27, the Medicines and Healthcare products Regulatory Agency started the rolling review process of mRNA-1273 ...
The agreement gives the commission the option to purchase an additional 80 million doses up to a total of 160 million
What’s the key to ensuring sterility when packaging prefilled syringes?
In the wake of patient-centricity in the pharmaceutical industry, drug delivery technologies have emerged as a central ...
In the wake of patient-centricity in the pharmaceutical industry, drug delivery technologies have emerged as a central ...
The company says its platform could also provide a universal coronavirus vaccine, complementing vaccines currently in ...
The line was developed using the company’s in-house cold storage technology